In the example of EGFR as a biomarker in another brain tumor type, GBM, its characterization was based on the retrospective analyses of relationships between treatment outcomes and EGFR gene expression in 87 newly diagnosed patients with GBM who were enrolled in clinical trials. Here, EGFR is linked to glioblastoma.